New York Life Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

New York Life Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,623	Closed	-$182K	–	836
2025 Q2	$182K	Buy	10,623 +966	+10%	+$41.2K	﹤0.01%	797
2025 Q1	$616K	Buy	9,657 +125	+1%	+$13.2K	0.01%	747
2024 Q4	$1.16M	Sell	9,532 -574	-6%	-$70.3K	0.01%	633
2024 Q3	$1.26M	Sell	10,106 -579	-5%	-$80K	0.01%	655
2024 Q2	$1.69M	Buy	10,685 +971	+10%	+$125K	0.02%	592
2024 Q1	$1.26M	Sell	9,714 -228	-2%	-$27.9K	0.01%	631
2023 Q4	$959K	Buy	9,942 +166	+2%	+$15.9K	0.01%	667
2023 Q3	$1.19M	Buy	9,776 +5,210	+114%	+$589K	0.01%	597
2023 Q2	$523K	Buy	+4,566	New	+$589K	0.01%	692

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

New York Life Investment Management's SRPT Position: Q3 2025 in Review

New York Life Investment Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 10,623 shares — an estimated $182K sold.

New York Life Investment Management first reported a position in SRPT in Q2 2023 and held it in 9 quarters. The position peaked at $1.69M in Q2 2024. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

New York Life Investment Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
New York Life Investment Management sold 10,623 Sarepta Therapeutics shares in Q3 2025, an estimated $182K.
New York Life Investment Management first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 9 quarters.
New York Life Investment Management's Sarepta Therapeutics position peaked at $1.69M in Q2 2024.
320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on New York Life Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.